spacer
home > events calendar
PHARMACEUTICAL INDUSTRY EVENTS CALENDAR
   
  
EVENTS FOR 2020
   
 
EVENTS FOR ALL MAGAZINES
 
     

Evolution Summit

20-22 July 2020
The Ritz Carlton, Fort Lauderdale, FL

The 22nd Evolution Summit is the premium forum bringing leading drug development executives and solution providers together. As an invitation-only event, taking place behind closed doors, the Summit offers an intimate environment for a focused discussion of key new drivers shaping drug development. More>>

 
web events.marcusevans-events.com/evolutionmay-2020/
email The Ritz Carlton, Fort Lauderdale, FL
 

INTERPHEX 2020

15-17 July 2020
Javits Center NYC

More>>

 
phone (203) 840-5455
email KScott@reedexpo.com
web bit.ly/2ET106L
email Javits Center, New York, USA
 

Formulation and Drug Delivery Series UK

8-9 July 2020
Oxford Global

This event brings together leading formulation, drug delivery and biologics manufacturing experts from around the world across two days. The panel of prominent industry leaders and world-leading scientists will share the latest case studies, innovative developments for novel therapeutic products and strategies for drug development. More>>

 
phone 01865 248455
email e.hawkings@oxfordglobal.co.uk
web https://bit.ly/2SXCR4w
email Search Results Godstow Court, Minns Business Park, Botley, Oxford OX2 0JB
 
spacer
Industry Events

Outsourcing in Clinical Trials Europe

26-27 October 2020, Paris, France

Arena International are delighted to announce the return of Outsourcing in Clinical Trials Europe. Part of our global series of events, this flagship show will attract the leading clinical professionals from across Europe. The 10th Annual event will be hosted in Paris.
More info >>

White Papers

Case Study: Cmed’s Mobile Data Management Solution

Cmed Clinical Services

The trial presented to Cmed was a randomized, double blinded, placebo and active controlled study to evaluate the cardiac safety of multiple doses of [study drug] in health volunteers. The pharmaceutical company, who were into the second year of development of a potential blockbuster compound for the treatment of chronic myelogenous leukaemia (CML), were requested by the FDA to design a trial to provide information on the cardiac safety of different dose levels of the study drug in healthy adult volunteers. The primary objective of the study was specifically to find the maximum tolerated dose before QTc levels became unsafe. All development of the compound was put on hold until the results of this study were submitted to the FDA and approval granted for the compound to progress into full development.
More info >>


News and Press Releases

Annual General Meeting of Gerresheimer AG approves dividend increase to EUR 1.20 per share

Duesseldorf, June 24, 2020—Payment of a dividend of EUR 1.20 per share was approved at the virtual Annual General Meeting of Gerresheimer AG.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement